ArticlemBio2017
Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.
Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.Frontiers in immunology · 2023Pooled it
- New approach methodologies in nanomedicine: bridging the gap betweenChemical Society reviews · 2026Review
- RNA-DNA Fusomer Fibers With Customizable Physicochemical, Mechanical, and Biological Properties for Next-Generation Therapeutics.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Effectiveness and immunogenicity of a nanoemulsion protein subunit vaccine against Pseudomonas aeruginosa: investigation in diet-induced obese mice.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Licensed and investigational TLR4 agonists as vaccine adjuvants: structural basis, clinical progress, and future directions.Frontiers in immunology · 2026Review
- Comparative immunogenicity and protective efficacy of BECC438 and BECC470 adjuvants in a vaccine formulation againstFrontiers in immunology · 2026Article
- From Sequence to Response: AI-Guided Prediction of Nucleic Acid Nanoparticles Immune Recognitions.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Article
- Lipid A mimetic BECC438 potentiates durable and balanced antibody responses in an ovalbumin murine model of vaccination.ImmunoHorizons · 2025Article
- A critical role forProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Reconfigurable Nucleic Acid Nanoparticles with Therapeutic RNAi Responses to Intracellular Disease Markers.Advanced functional materials · 2025Article
- The evaluation of a novel multi-epitope vaccine against human papillomavirus and Candida albicans.Journal, genetic engineering & biotechnology · 2025Article
- Structural insight into TLR4/MD-2 activation by synthetic LPS mimetics with distinct binding modes.Nature communications · 2025Article
- BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in mice.Vaccine · 2025Article
- Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.Vaccine · 2025Article
- Development of human mycoplasma vaccines: navigating the IL-17A paradox.Frontiers in immunology · 2025Review
- BECC-engineered live-attenuatedResearch square · 2024Article
- BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models.Infection and immunity · 2024Article
- The O-glycan is essential for the induction of protective antibodies against lethal infection by flagella A-bearingInfection and immunity · 2024Article
- Solid Lipid Nanoparticles Delivering a DNA Vaccine EncodingInternational journal of molecular sciences · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Adjuvant properties of bacterial cell wall components like MPLA (monophosphoryl lipid A) are well described and have gained FDA approval for use in vaccines such as Cervarix. MPLA is the product of chemically modified lipooligosaccharide (LOS), altered to diminish toxic proinflammatory effects while retaining adequate immunogenicity. Despite the virtually unlimited number of potential sources among bacterial strains, the number of useable compounds within this promising class of adjuvants are few. We have developed bacterial enzymatic combinatorial chemistry (BECC) as a method to generate rationally designed, functionally diverse lipid A. BECC removes endogenous or introduces exogenous lipid A-modifying enzymes to bacteria, effectively reprogramming the lipid A biosynthetic pathway. In this study, BECC is applied within an avirulent strain of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.